NEW YORK (GenomeWeb News) – Knome has announced that its services division will now offer Omixon's targeted human leukocyte antigen typing capabilities as part of its whole genome and exome interpretation pipelines.
Omixon CEO Attila Berces said in a statement that the HLA typing service should help pharmaceutical companies that utilize Knome's services to identify drug response biomarkers, "shorten the time to approval, and reduce the risk of late-stage failures."
Commenting on the newly minted partnership, Knome CEO Wolfgang Daum said that Omixon's applications address "the major problems associated with HLA calling."
Financial terms of the agreement were not disclosed.